Sirolimus

30 trials 16 recruiting LOncology Orphan designation

Filter these 30 trials by condition, phase, country and more.

Open in Search →

30 Registered trials

16 Recruiting

6 Completed trials

24 Sponsors

11 Countries

Phase III

Phase II

Phase IV

Phase I (FiH)

Phase III: 3 Phase II/III: 2 Phase II: 15 Phase I/II: 2 Phase IV: 4 Phase I (FiH): 4

Oversight events:

8 temporary halts 1 urgent safety measure 1 unexpected event across 4 trials

View oversight register →

Indications tested

Crigler-Najjar syndrome 2 Muscular dystrophy 1 Complications of transplanted kidney 1 Familial dilated cardiomyopathy 1 Lymphatic malformation 1 Duchenne muscular dystrophy 1 Gaucher's disease type I 1 COVID-19 1 Frontotemporal dementia 1

Sponsors using this IMP

Instytut Pomnik Centrum Zdrowia Dziecka 5 Genethon 3 Centre Hospitalier Universitaire De Nantes 2 Prevail Therapeutics Inc. 2 Aft Pharmaceuticals Limited 1 Alexion Pharmaceuticals Inc. 1 Assistance Publique Hopitaux De Paris 1 Atamyo Therapeutics 1 Azienda Ospedaliero Universitaria Di Modena 1 Biodexa Limited 1 Centre Hospitalier Regional Universitaire De Tours 1 Centre Hospitalier Universitaire Amiens Picardie 1

All trials — page 2

30 total

A dose finding study of LY3884961 in patients with Gaucher disease Halted

2022-500281-10-02 Phase I/II 2 countries Prevail Therapeutics Inc.
Open-label study to assess safety and efficacy of rapamycin in drugresistant epilepsy associated with mTOR pathway pathologies Ended

2024-515950-25-00 Phase II 1 country Instytut Pomnik Centrum Zdrowia Dziecka
Phase 2a, Random, double masked, Placebo-controlled, side by side group, multiple center study evaluating the effectiveness and safety of ST… Ended

2024-517104-11-00 Phase II 1 country Santen Inc.
Clinical study to assess safety and efficacy of rapamycin in paediatric high grade glioma Ended

2024-515951-39-00 Phase II 1 country Instytut Pomnik Centrum Zdrowia Dziecka
TOPical sirolimus in linGUal microkystic lymphatic malformation Ended

2024-515955-39-01 Phase II 1 country Centre Hospitalier Regional Universitaire De Tours
Evaluation and promotion of specific adaptative immunity against polyomavirus (BKV) to prevent viral infection after kidney transplantation … Expired

2023-504309-35-00 Phase IV 1 country Fir Huvh Fundacio Institut De Recerca Hospital Universitari Vall De Hebron

Showing 25–30 of 30 trials

← All drugs A–Z